论文部分内容阅读
Cromakalim(BRL34915)是一新型抗高血压药物,其作用为激活细胞膜上的K~+通道,使K~+电导增强,细胞膜超极化,从而引起电压依赖性Ca~(2+)通道关闭,细胞内Ca~(2+)浓度减低,心肌抑制,平滑肌张力降低。药理作用和临床用途有:[舒张血管,治疗高血压]清醒的肾性高血压大鼠实验表明,经口给予Cromalaim后,能产生剂量相关的降压作用,其效价强度与Ca~(2+)拮抗剂硝苯吡啶相似,但Cromakalim可降低肾血管阻力,增加肾血流量,而硝苯吡啶无此作用,血管紧张素转化酶抑制剂实则降低肾血流量,Cromakalim这一特点对高血压病人,尤其是伴有肾功能损伤的老年高血压病人有
Cromakalim (BRL34915) is a new type of antihypertensive drug. Its function is to activate the K ~ + channels on the cell membrane, enhance the conductance of K ~ +, and hyperpolarize the cell membrane, resulting in the voltage-dependent Ca 2+ channel closure. Intracellular Ca2 + concentration decreased, myocardial inhibition, smooth muscle tension decreased. Pharmacological effects and clinical uses are: [Diastolic blood vessels, the treatment of hypertension] Awake renal hypertensive rat experiments show that oral administration of Cromalaim, can produce dose-related antihypertensive effect, the potency and Ca ~ (2 +) Antagonist nifedipine similar, but Cromakalim can reduce renal vascular resistance and increase renal blood flow, nifedipine without this effect, but in fact angiotensin converting enzyme inhibitors reduce renal blood flow, Cromakalim this feature of hypertension Patients, especially those with hypertensive renal impairment have